Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of repeat-dose rimegepant for acute migraine
MOH_2026-06-21_016886Phase 4Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rimegepant in migraine, sponsored by Pfizer. Primary endpoint: Safety and tolerability of repeat-dose rimegepant. Started Jun 2026; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on MOH_2026-06-21_016886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-21_016886.